Faron Announces Positive FDA Feedback
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside Information: Faron Announces Positive FDA Feedback Company announcement, Inside Information, 11 July 2024 at 7:00 a.m. BST / 9:00 a.m. EEST Key highlights - Faron had a formal meeting with the FDA to discuss the registrational clinical development plan for bexmarilimab in the treatment myelodysplastic syndrome (MDS). - The FDA acknowledged the difficulties of running a randomized study with a comparator in the relapsed / refractory setting (r/r) and instead proposed that